Mental Health Clinical Trials 2026: Depression, Anxiety, and Psychiatric Studies

Psychiatric drug development spent the 1990s and 2000s largely recycling the same monoamine targets — serotonin, norepinephrine, dopamine — with diminishing returns and no real mechanistic innovation. What changed in 2026 is the convergence of several distinct developments: esketamine proved that NMDA receptor modulation produces rapid, durable antidepressant effects that SSRIs cannot; psilocybin Phase 2 trials produced remission rates that traditional psychiatry didn't think were achievable; MDMA-assisted therapy showed 67% PTSD remission in Phase 3; and the SAINT protocol for accelerated TMS achieved 78.6% remission in TRD Phase 2. These aren't incremental improvements. Something genuinely different is happening in psychiatric clinical research.

Treatment-Resistant Depression: Esketamine and What Comes Next

Treatment-resistant depression (TRD) — conventionally defined as failure of at least two adequate antidepressant trials — affects an estimated 30% of people with major depressive disorder. That's millions of patients who have been told to "try another antidepressant" with steadily diminishing expectations.

Esketamine (Spravato, Janssen) nasal spray received FDA approval in 2019 as the first TRD treatment with a genuinely novel mechanism since the original SSRIs. The Phase 3 TRANSFORM-2 trial showed 54.0% response at 4 weeks vs. 31.0% for placebo — a meaningful separation — and SUSTAIN-2 demonstrated durability: 26.7% relapse rate with esketamine vs. 45.3% with placebo in sustained responders over 52 weeks. The drug's effect onset is rapid (within hours to days), distinct from SSRIs' 4–6 week lag, and the mechanism involves NMDA receptor modulation and downstream AMPA receptor potentiation leading to rapid synaptogenesis.

Current trials are pushing esketamine earlier in the treatment algorithm. ESCAPE-TRD evaluates esketamine in patients who have failed just one antidepressant — if positive, this would change the definition of "treatment-resistant" and expand the eligible population substantially. Other trials are testing optimized maintenance dosing schedules (weekly vs. biweekly) and combinations with psychotherapy protocols designed to leverage the neuroplasticity window that esketamine appears to open.

Zuranolone (Zurzuvae, Biogen/Sage Therapeutics) received FDA approval in August 2023 for major depressive disorder and postpartum depression as a 14-day oral treatment course — distinct from esketamine in mechanism (GABA-A receptor positive allosteric modulator, neuroactive steroid) and distinctive in its finite treatment duration: patients take it for two weeks and response persists well beyond drug clearance in many cases. SHORELINE trial long-term data show 71.3% of patients who responded maintained improvement through 12 months with on-demand retreatment cycles. Trials are now testing zuranolone for bipolar depression and PMDD.

Psilocybin: Phase 3 Is Now Real

Psilocybin entered Phase 3 trials carrying Phase 2 data that psychiatrists found difficult to fully accept — the effect sizes were too large, the durability too unusual, the mechanism too different from anything in the pharmacological armamentarium. The COMPASS Phase 2b trial (COMP360, synthetic psilocybin 25mg with psychological support, TRD) showed 29.1% remission at 3 weeks vs. 7.6% for placebo. A Johns Hopkins Phase 2 showed comparable results in treatment-resistant major depression. These weren't marginal improvements — they were categorical shifts in the proportion of patients who achieved something that looked like recovery rather than symptom reduction.

Phase 3 programs now enrolling: COMPASS Pathways' COMP360 Phase 3 for TRD and the Usona Institute's EPIC-MDD Phase 3 for major depressive disorder are both recruiting in the US, UK, Canada, and Australia. FDA has granted Breakthrough Therapy Designation to both programs, providing an accelerated review pathway. The regulatory and scheduling challenges are real — psilocybin remains Schedule I — but the clinical data has become compelling enough that the FDA pathway is now defined and being actively navigated.

For cancer-related existential distress and anxiety, Phase 2 data from NYU and Johns Hopkins show that two psilocybin sessions produced sustained reductions in anxiety and depression in patients with cancer diagnoses — effects lasting months in most patients. Phase 3 trials for this indication are enrolling separately from the TRD/MDD programs.

PTSD: MDMA-AT and the Stellate Ganglion Block

MDMA-assisted therapy for PTSD produced the most striking Phase 3 psychiatric data in recent memory. The MAPP1 trial (MAPS) showed 67% of PTSD participants no longer met diagnostic criteria after three MDMA-AT sessions (each involving 8-hour therapy sessions with active MDMA doses) vs. 32% for therapy plus placebo. The FDA didn't approve the application in 2024, citing statistical analysis concerns and manufacturing issues — not questioning the underlying efficacy. The MAPP3 follow-on trial is now enrolling to address those concerns, and MDMA-AT is currently approved and practiced in Australia (since February 2023), providing additional real-world safety data to support the FDA resubmission.

Stellate ganglion block (SGB) — an anesthetic injection near the stellate ganglion in the cervicothoracic region, targeting the autonomic dysregulation hypothesized to maintain PTSD hyperarousal — showed 70% response rate vs. 20% for sham in the SPRINT Phase 2 trial. The VALOR Phase 3 (stellate ganglion block vs. sham in active-duty military with PTSD) is enrolling. The mechanism remains debated, but the clinical signal is real enough to justify Phase 3 evaluation.

Ibogaine deserves specific attention. A Stanford Medicine open-label study in 30 veterans with severe treatment-resistant PTSD administered a single ibogaine treatment in a medically supervised setting in Mexico (where it's legal). Results: 87% no longer meeting PTSD criteria at one-month follow-up, with large reductions in depression and anxiety scores as secondary endpoints. Phase 1/2 trials are now underway at Stanford and through MAPS. The scheduling challenge is similar to MDMA — ibogaine is Schedule I — but the veteran PTSD data is generating significant Congressional interest and regulatory attention.

Neurostimulation: The SAINT Protocol and What It Means for TMS

Standard TMS for TRD delivers 36 sessions over 6 weeks — the timeline itself is a barrier for many patients with severe depression. The SAINT protocol (Stanford Accelerated Intelligent Neuromodulation Therapy) delivers 10 sessions in a single day using personalized targeting based on resting-state fMRI to identify the dorsolateral prefrontal cortex subregion most anti-correlating with the subgenual anterior cingulate cortex. Phase 2 data showed 78.6% remission rate at one month — compared to roughly 30% for standard TMS in similar populations. Magnus Medical has commercialized this as the SMA-TMS system and Phase 3 evaluation is ongoing.

Deep brain stimulation for TRD has a complicated history — the BROADEN trial failed in 2013 after a promising pilot. The field has regrouped with next-generation closed-loop DBS systems (Medtronic Summit RC+S, Abbott Infinity) that adapt stimulation parameters in real time based on local field potential biomarkers, and with much more rigorous patient selection using neuroimaging phenotyping. Phase 2 trials at UCSF, Emory, and Mayo Clinic are ongoing. It's too early to say whether closed-loop DBS will succeed where open-loop failed, but the biological logic has never been more sound.

Eligibility and How to Find Psychiatric Trials

Psychiatric trial eligibility requires formal DSM-5 diagnosis confirmed by a structured clinical interview (MINI or SCID), specific severity thresholds on validated scales (MADRS ≥20–26 for most MDD/TRD trials; PCL-5 ≥31–33 for PTSD; HAM-A ≥18 for anxiety), documented prior treatment failures for TRD studies, and medication stability before screening. Standard exclusion criteria include active suicidal ideation with intent or plan, current psychosis, active substance use disorder, cardiovascular contraindications for certain compounds, and pregnancy. Most psychedelic therapy trials require washout from prior psychiatric medications — typically 5 half-lives — before study drug dosing.

ClinicalTrials.gov searches using condition terms ("Major Depressive Disorder," "Post-Traumatic Stress Disorder," "Generalized Anxiety Disorder") with Recruiting status yield hundreds of options. The NIMH clinical trials portal lists NIH-funded psychiatric studies. MAPS (maps.org), Usona Institute (usonainstitute.org), and COMPASS Pathways (compasspathways.com) each maintain dedicated trial registries for their programs. Most psychiatric trials offer participant compensation given the typically intensive visit schedules involved.

Key Takeaways

• Psilocybin Phase 3 trials (COMP360, Usona EPIC-MDD) are enrolling patients with TRD following Phase 2 remission rates of 29% vs. 7.6% placebo at 3 weeks — with effects lasting months after a single session.
• The SAINT protocol (10 TMS sessions in one day) showed 78.6% TRD remission in Phase 2 — substantially above standard TMS response rates. Phase 3 is underway under FDA review.
• MDMA-assisted therapy for PTSD achieved 67% remission in MAPP1 Phase 3; the MAPP3 follow-on is enrolling. Australia has approved MDMA-AT since 2023, providing ongoing safety data.
• Ibogaine for veteran PTSD showed 87% no longer meeting criteria in Stanford open-label data; Phase 1/2 trials are underway with Phase 3 design contingent on regulatory scheduling decisions.
• Eligibility for most psychiatric trials requires formal DSM-5 diagnosis with validated scale scores, documented prior treatment failures, and organized medication history records — having this information ready significantly accelerates screening.